Juan Andres - 02 Nov 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Technical Operations and Quality Officer
Issuer ticker: MRNA
Reported as of: 02 Nov 2022
Net transaction value: -$266,540
SEC form: 4
Accepted by SEC: 04 Nov 2022, 16:12:41 UTC
Prior SEC filing: 31 Oct 2022
Next SEC filing: 14 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian Sandstrom, as Attorney-in-Fact

Key filing fact

Juan Andres filed Form 4 for Moderna, Inc. (MRNA) on 04 Nov 2022.

Key facts

This page summarizes Juan Andres's Form 4 filing for Moderna, Inc. (MRNA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2022, 16:12.

Change

Previous filing in this sequence was filed on 31 Oct 2022.
Current net transaction value: -$266,540.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Options Exercise

Transaction value: $41,860
Shares: +2,000
Change %: +17%
Price: $20.93^*
Shares after: 13,566
Date: 02 Nov 2022
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $308,400
Shares: -2,000
Change %: -15%
Price: $154.20
Shares after: 11,566
Date: 02 Nov 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -2,000
Change %: -0.9%
Price: $0.000000
Shares after: 219,025
Date: 02 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $20.93
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.

Footnote F2

25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC remarks

Chief Technical Operations and Quality Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .